---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-016224"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2025-01-30T23:59:59+00:00"
generated_at: "2026-05-27T05:35:02.943578+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TX45 Phase 1b data show 17.9% PCWP reduction in PH-HFpEF; >30% PVR cut in CpcPH subgroup

## Summary
- TX45 achieved 17.9% reduction in PCWP (overall population) and >30% reduction in PVR in CpcPH patients.
- Cardiac output increased 17.4%; mean pulmonary artery pressure reduced 15.9% across the total study.
- No serious/severe adverse events, discontinuations, or significant hypotension; well tolerated.
- APEX Phase 2 trial in PH-HFpEF is underway; topline results expected in 2026.
- Data support enrichment of CpcPH patients in APEX; Part B of Phase 1b (PH-HFrEF) starts February 2025.

## SEC filing metadata
- accession: 0001193125-25-016224
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2025-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312525016224/0001193125-25-016224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312525016224/d817477d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-016224
- JSON: https://secwatch.observer/filing/0001193125-25-016224.json
- Plain text: https://secwatch.observer/filing/0001193125-25-016224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.